Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The 34th annual JP Morgan Healthcare Conference is being held in San Francisco, CA from January 11- 14, 2016. A list of events and catalysts that were announced or updated at the conference today is included in this report. Additionally, below are some key points from today’s company presentations. Drug pricing has received a lot of negative press, so at the opening luncheon, it was interesting to hear JPM Chairman and CEO, Jaime Dimon suggest that nothing would really change with a new administration. He did add, however, that a new administration could address tax policy that would affect acquisitions that effectively move companies overseas like the recent Pfizer-Allergan deal.
Drug pricing has received a lot of negative press, so at the opening luncheon, it was interesting to hear JPM Chairman and CEO, Jaime Dimon suggest that nothing would really change with a new administration. He did add, however, that a new administration could address tax policy that would affect acquisitions that effectively move companies overseas like the recent Pfizer-Allergan deal.
In Vivo: strategic insights for life sciences decision-maker...
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
Scrip: industry news and insights
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topics Business strategies Drug approval Drug development landscape Drug review
Scrip: industry news and insights
By Emily Hayes
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Looking for more products Product Finder
